TIDMOXB
RNS Number : 8009D
Oxford Biomedica PLC
23 June 2023
Oxford Biomedica
Result of Annual General Meeting
Oxford, UK - 23 June 2023: Oxford Biomedica plc (LSE:OXB)
("Oxford Biomedica" or "the Company") , a quality and
innovation-led viral vector CDMO , announces today that all
resolutions proposed were duly passed at its Annual General Meeting
(AGM), held at 3pm on 23 June 2023 in Oxford. As proposed in the
Notice of AGM, all resolutions were decided by poll vote.
The full text of all the resolutions can be viewed in the Notice
of Meeting by visiting the Company's website at www.oxb.com
Copies of the document setting out the above resolutions passed
at the 2023 AGM have been submitted to the National Storage
Mechanism and will shortly be available for inspection at:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
On the Record Date (21 June 2023) there were 96,521,209 ordinary
shares of 50 pence each in issue, each carrying one vote per
share.
Votes
For (incl.
Resolution votes % of %
at the votes of Total
Chairman's cast Votes votes Votes votes
discretion) Against cast Withheld* cast Result
Ordinary resolutions
-------------------------------------------- -------- ----------- -------- ------------ ----------- -------
To receive the
Company's Accounts,
the Reports
of the Directors
and Auditor
and the Strategic
Report for the
year ended 31
1 December 2022. 73,060,750 100.00% 629 0.00% 146,857 73,061,379 PASS
---------------------------- -------------- -------- ----------- -------- ------------ ----------- -------
To receive the
Directors' Remuneration
Report and the
Report of the
Auditor on the
Remuneration
Report for the
year ended 31
2 December 2022. 51,080,127 79.93% 12,826,613 20.07% 9,301,496 63,906,740 PASS
---------------------------- -------------- -------- ----------- -------- ------------ ----------- -------
To appoint Dr.
Frank Mathias
3 as a Director. 73,062,102 99.81% 137,244 0.19% 8,890 73,199,346 PASS
---------------------------- -------------- -------- ----------- -------- ------------ ----------- -------
To appoint Leone
Patterson as
4 a Director. 72,892,590 99.58% 307,356 0.42% 8,290 73,199,946 PASS
---------------------------- -------------- -------- ----------- -------- ------------ ----------- -------
To reappoint
Dr. Roch Doliveux
5 as a Director. 67,536,075 92.26% 5,662,468 7.74% 9,693 73,198,543 PASS
---------------------------- -------------- -------- ----------- -------- ------------ ----------- -------
To reappoint
Professor Dame
Kay Davies as
6 a Director. 66,057,059 90.24% 7,141,705 9.76% 9,472 73,198,764 PASS
---------------------------- -------------- -------- ----------- -------- ------------ ----------- -------
To reappoint
Stuart Paynter
7 as a Director. 72,551,391 99.11% 649,338 0.89% 7,507 73,200,729 PASS
---------------------------- -------------- -------- ----------- -------- ------------ ----------- -------
To reappoint
Stuart Henderson
8 as a Director. 66,051,339 90.25% 7,139,682 9.75% 17,215 73,191,021 PASS
---------------------------- -------------- -------- ----------- -------- ------------ ----------- -------
To reappoint
Dr. Heather
Preston as a
9 Director 64,485,621 88.10% 8,713,178 11.90% 9,437 73,198,799 PASS
---------------------------- -------------- -------- ----------- -------- ------------ ----------- -------
To reappoint
Robert Ghenchev
10 as a Director. 73,059,336 99.81% 140,259 0.19% 8,641 73,199,595 PASS
---------------------------- -------------- -------- ----------- -------- ------------ ----------- -------
To reappoint
Dr. Michael
Hayden as a
11 Director. 67,826,937 92.66% 5,371,827 7.34% 9,472 73,198,764 PASS
---------------------------- -------------- -------- ----------- -------- ------------ ----------- -------
To reappoint
Catherine Moukheibir
12 as a Director. 68,240,515 93.22% 4,959,431 6.78% 8,290 73,199,946 PASS
---------------------------- -------------- -------- ----------- -------- ------------ ----------- -------
To reappoint
Namrata P. Patel
13 as a Director. 73,140,356 99.92% 59,590 0.08% 8,290 73,199,946 PASS
---------------------------- -------------- -------- ----------- -------- ------------ ----------- -------
To appoint
PriceWaterhouseCoopers
14 LLP as auditor. 73,193,707 99.99% 7,290 0.01% 7,239 73,200,997 PASS
---------------------------- -------------- -------- ----------- -------- ------------ ----------- -------
To authorise
the Directors
to agree the
remuneration
15 of the auditor. 73,195,908 99.99% 4,776 0.01% 7,552 73,200,684 PASS
---------------------------- -------------- -------- ----------- -------- ------------ ----------- -------
To authorise
the Directors
16 to allot shares. 70,498,713 96.31% 2,702,643 3.69% 6,880 73,201,356 PASS
---------------------------- -------------- -------- ----------- -------- ------------ ----------- -------
Special resolutions
-------------------------------------------- -------- ----------- -------- ------------ ----------- -------
To authorise
the Directors
to disapply
pre-emption
17 rights. 72,202,544 98.64% 996,404 1.36% 9,288 73,198,948 PASS
---------------------------- -------------- -------- ----------- -------- ------------ ----------- -------
To authorise
the Directors
to further disapply
pre-emption
rights for acquisitions
and specified
18 capital investments. 70,474,362 96.28% 2,721,812 3.72% 12,062 73,196,174 PASS
---------------------------- -------------- -------- ----------- -------- ------------ ----------- -------
To permit the
Directors to
convene general
meetings (other
than annual
general meetings)
on not less
than 14 days'
19 notice. 71,049,162 97.06% 2,150,941 2.94% 8,133 73,200,103 PASS
---------------------------- -------------- -------- ----------- -------- ------------ ----------- -------
* A vote withheld is not a vote in law and is not counted
towards votes cast in respect of a resolution.
In addition, further to the announcement by the Company in
January, Dr. Siyamak Rasty has stepped down from the Company's
Board of Directors with effect from the conclusion of today's
AGM.
The Board recognises that, whilst resolution 2 was passed with a
clear majority at almost 80%, there was also a significant vote
against this resolution. The Board will seek to engage with those
shareholders who voted against this resolution and it is
anticipated that a revised remuneration policy will be presented to
shareholders for their approval at the Company's AGM in 2024. In
accordance with the UK Corporate Governance Code, an update on the
views received from shareholders and details of any further actions
taken by the Company will be published no later than 23 December
2023 by way of Stock Exchange Announcement. A summary will also be
published in the 2023 Annual Report and Accounts.
-Ends-
Enquiries:
Oxford Biomedica plc:
Taylor Boyd, VP, Head of IR - T: +1 (984) 268 8488/ E: ir@oxb.com
Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0)
7394 562 425 / E: ir@oxb.com
Consilium Strategic Communications:
T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com
Mary-Jane Elliott / Matthew Neal / Davide Salvi
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led
viral vector CDMO with a mission to enable its clients to deliver
life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the
Company has more than 25 years of experience in viral vectors; the
driving force behind the majority of gene therapies. The Company
collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV) and adenoviral vectors. Oxford
Biomedica's world-class capabilities span from early-stage
development to commercialisation. These capabilities are supported
by robust quality-assurance systems, analytical methods and depth
of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in
Oxford, UK. It has locations across Oxfordshire, UK and a US-based
subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US.
Learn more at www.oxb.com , www.oxbsolutions.com , and follow us on
LinkedIn , Twitter and YouTube .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGSESFMDEDSEDM
(END) Dow Jones Newswires
June 23, 2023 12:32 ET (16:32 GMT)
Oxford Biomedica (AQSE:OXB.GB)
Historical Stock Chart
From Dec 2024 to Jan 2025
Oxford Biomedica (AQSE:OXB.GB)
Historical Stock Chart
From Jan 2024 to Jan 2025
